Savings Card & Support | LOKELMA for Oral Suspension

References: 1.Data on File, US-53732. AZPLP. 2. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 3. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223-2233. doi:10.1001/jama.2014.156884. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia [article and supplementary material]. N Engl J Med. 2015;372(3):222-231. doi:10.1056/NEJMoa1411487 5. Spinowitz BS, Fishbane S, Pergola PE, et al; ZS-005 Study Investigators. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798-809. doi:10.2215/CJN.12651018

References: 1. Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21(15):S307-S315. 2. Data on File, REF-34835. AZPLP. 3. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213-221. 4. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3 Suppl):S1-S13. 5. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 6. Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385-393. 7. Cupisti A, Kovesdy CP, D'Alessandro C, et al. Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function. Nutrients. 2018;10(261):1-159. 8. Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Nutrition in CKD Guideline Work Group. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76(3)(suppl 1):S1-S107. 9. Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744-762. 10. Downer MK, Gea A, Stampfer M, et al. Predictors of short- and long-term adherence with a Mediterranean-type diet intervention: the PREDIMED randomized trial. Int J Behav Nutr Phys Act. 2016;13:67. 11. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 suppl):S212-S220. 12. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. 13. Kidney Disease: Improving Global Outcomes. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. 14. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician. 2006;73(2):283-290. 15. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246-3251. 16. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J. 2006;33(1):40-47. 17. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10:1050-1060. 18. Mushiyakh Y, Dangaria H, Qavi S, Ali N, Pannone J, Tompkins D. Treatment and pathogenesis of acute hyperkalemia. J Community Hosp Intern Med. 19. Rafique Z, Peaco*ck F, Armstead T, et al. Hyperkalemia management in the emergency department: An expert panel consensus. JACEP Open. 2021;2:e12572.

References: 1. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 2. Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K⁺ selective ion trap. PLoS One. 2014;9(12):e114686. 3. Kayexalate^® (sodium polystyrene sulfonate) [prescribing information]. St. Michael, Barbados: Concordia Pharmaceuticals Inc; 2017. 4. Veltassa^® (patiromer) [prescribing information]. Redwood City, CA: Relypsa, Inc; 2021. 5. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension. 2015;66(4):731-738. 6. Palmer BF. Potassium binders for hyperkalemia in chronic kidney disease–diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo Clin Proc. 2020;95(2):339-354. 7. Clegg DJ, Cody M, Palmer BF. Challenges in treating cardiovascular disease: restricting sodium and managing hyperkalemia. Mayo Clin Proc. 2017;92(8):1248-1260. 8. Lien YH. Patiromer: Can less be better than more? Am J Med. 2018;131(5):459-460. 9. Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic review and meta-analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherapy. 2017;37(4):401-411. 10. Beccari MV, Meaney CJ. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. Core Evid. 2017;12:11-24. 11. Sodium Polystyrene Sulfonate Suspension [package insert]. Farmville, North Carolina: CMP Pharma Inc; 2015. 12. Li L, Harrison SD, Cope MJ, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther. 2016;21(5):456-465.

References: 1. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 2. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia [article and supplementary material]. N Engl J Med. 2015;372(3):222-231. 3. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223-2233. 4. Spinowitz BS, Fishbane S, Pergola PE, et al; ZS-005 Study Investigators. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798-809. 5. Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473-480. 6. Data on file, US-53732, AZPLP. 7. Fishbane S, Ford M, f*ckagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol. 2019;30(9):1723-1733.

References: 1. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 2. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia [article and supplementary material]. N Engl J Med. 2015;372(3):222-231. 3. Spinowitz BS, Fishbane S, Pergola PE, et al; ZS-005 Study Investigators. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798-809. 4. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223-2233. 5. Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473-480. 6. U.S. Food & Drug Administration. Drug Approval Package: LOKELMA (sodium zirconium cyclosilicate) Medical Review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207078Orig1s000MedR.pdf. Accessed September 9, 2021. 7. Fishbane S, Ford M, f*ckagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol. 2019;30(9):1723-1733.

References: 1. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 2. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223-2233. 3. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia [article and supplementary material]. N Engl J Med. 2015;372(3):222-231. 4. Spinowitz BS, Fishbane S, Pergola PE, et al; ZS-005 Study Investigators. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798-809. 5. Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473-480.

References: 1. Spinowitz BS, Fishbane S, Pergola PE, et al; ZS-005 Study Investigators. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798-809. 2. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia [article and supplementary material]. N Engl J Med. 2015;372(3):222-231. 3. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223-2233. 4. Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473-480. 5. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 6. Data on file, US-53732, AZPLP.

References: 1. Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care.2015;21(15 Suppl):s307-s315. 2. Data on File, REF-34835. AZPLP. 3. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol.2017;46(3):213-221. doi:10.1159/0004798024. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3 Suppl):S1-S13. 5. LOKELMA^® (sodium zirconium cyclosilicate) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2022. 6.Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385-393 2017;46(3):213-221. doi:10.1016/j.ekir.2017.11.0037. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 suppl):S212-S220. 8.Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127. doi:10.10 S220. 816/j.kint.2022.06.0089. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019 10. Kidney Disease: Improving Global Outcomes. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003 11. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician. 2006;73(2):283-290. 12. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246-3251. doi:10.1097/CCM.0b013e31818f222b 13. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J. 2006;33(1):40-47. 14. Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol. 2015;10(6):1050-1060. doi:102215/CJN.08580813 15. Mushiyakh Y, Dangaria H, Qavi S, Ali N, Pannone J, Tompkins D. Treatment and pathogenesis of acute hyperkalemia. J Community Hosp Intern Med Perspect. 2012;1(14):10.3402/jchimp.v1i4.732. doi:10.3402/jchimp.vi4.7372 16. Rafique Z, Peaco*ck F, Armstead T, et al. Hyperkalemia management in the emergency department: An expert panel consensus.J Am Coll Emerg Physicians Open. 2021;2(5):e12572. doi:10.1002/emp2.12572

References: 1. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21:S212-S220. 2. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Working Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. 3. Kidney Disease: Improving Global Outcomes. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. 4. Data on File, US-53732, AZPLP.

FAQs

How long does it take for Lokelma to work? ›

LOKELMA starts to lower your potassium within one hour of taking it. The amount of decrease depends on your starting potassium level. Most patients have normal levels within 24 to 48 hours of treatment.

Tell Me More ›

How to get Lokelma for free? ›

Eligible commercially insured patients with a valid prescription for LOKELMA^® (sodium zirconium cyclosilicate) who present this savings card at participating pharmacies will pay as low as $0 for up to a 30-packet supply, subject to a maximum savings of $350 per 30-packet supply; patient out-of-pocket expenses may vary.

Which is better Veltassa or Lokelma? ›

Lokelma has an average rating of 5.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 50% reported a negative effect. Veltassa has an average rating of 5.9 out of 10 from a total of 10 ratings on Drugs.com.

Explore More ›

Can you take Lokelma every other day? ›

Your doctor may direct you to start taking this medication 3 times a day for the first 48 hours, then decrease to once daily, or once every other day. Patients on dialysis should only take this medication on non-dialysis days. Follow your doctor's instructions carefully.

Read On ›

What are symptoms of potassium deficiency? ›

Potassium deficiency (hypokalaemia) is when a person has abnormally low levels of potassium in their body. Some people with potassium deficiency don't experience any symptoms, but others will notice muscle weakness, muscle cramps and an abnormal heart rhythm (arrhythmia).

How fast do potassium binders work? ›

Most people who have hyperkalemia don't have symptoms. However, potassium binders start to lower your potassium levels within 24 hours.

Learn More Now ›

How much does Lokelma cost? ›

The lowest GoodRx price for the most common version of Lokelma is around $758.38, 11% off the average retail price of $859.74. Compare potassium binders.

Can you buy Lokelma over the counter? ›

LOKELMA is a prescription medication for the treatment of high levels of potassium in the blood (hyperkalemia) in adults.

How long can you be on Lokelma? ›

When to take. For treating high levels of potassium, Lokelma is typically taken three times per day, for up to 2 days (48 hours). If your doctor determines that you should continue taking Lokelma for more than 2 consecutive days, your dose will most likely be 10 g taken once a day.

Show Me More ›

Does Lokelma cause increased bowel movements? ›

No, diarrhea and constipation aren't side effects of Lokelma. If you have problems with your digestive system, such as severe constipation or a blockage in your intestines, Lokelma can make your symptoms worse. Having severe diarrhea can cause you to lose electrolytes (minerals), such as potassium.

Learn More Now ›

What is the risk of Lokelma? ›

Taking Lokelma raises your risk for low potassium level, especially if you have medical conditions or are taking medications that lower your potassium level.

Discover More Details ›

What can I take instead of Lokelma? ›

Lokelma Alternatives Compared

Lokelma (sodium zirconium cyclosilicate)	Calcium gluconate	Sodium bicarbonate
Dosage Form(s) Available
Oral powder for reconstitution	Injectable solution Intravenous solution	Compounding powder Intravenous solution Oral tablet
Brand Names
N/A	Cal-G, Cal-GLU, Kalcinate	Bell/ans, Neut

39 more rows

Show Me More ›

How much does Lokelma bring down potassium? ›

In patients administered 10 g TID, the mean serum potassium reduction was -0.7 mEq/L at 48 hours. Patients with higher starting potassium levels had a greater response to LOKELMA.

View Details ›

What can be the cause of high potassium? ›

Dehydration (which is when the body doesn't have enough water and other fluids to work properly) Destruction of red blood cells due to severe injury or burns. Excessive use of potassium supplements. Type 1 diabetes.

Can Lokelma cause fluid retention? ›

The most common side effect of LOKELMA is swelling in your body caused by fluid retention. Tell your doctor if you have any side effects.

Is Lokelma fast acting? ›

Studies show that Lokelma is effective for lowering potassium levels in the blood. The drug starts working within 1 hour. And with regular use, Lokelma keeps potassium levels in a normal range for as long as it's taken. Talk with your doctor to find out how long you'll need to take Lokelma.

Read The Full Story ›

How much potassium does Lokelma remove? ›

Lokelma 10 g administered three times daily lowered serum potassium by -0.7 mmol/L at 48 hours (p < 0.001 vs. placebo); statistically significant 14% potassium reduction was observed 1 hour after the first dose. Patients with higher starting potassium levels had a greater response to Lokelma.

How effective is Lokelma? ›

Potassium levels in the blood start to decline in one hour of the start of Lokelma therapy. In studies, normal potassium levels in the blood were reached in 2.2 hours (median time). Most patients (92%) had normal potassium levels within 48 hours.

Show Me More ›

What is the best time to take Lokelma? ›

LOKELMA can be taken with or without food.
People in the LOKELMA studies did not have to be on a low-potassium diet.
If you have been prescribed other oral medications, you may need to take LOKELMA 2 hours before or 2 hours after your medication.

See Details ›

Savings Card & Support | LOKELMA for Oral Suspension | For HCPs (2024)

FAQs

How long does it take for Lokelma to work? ›

What is the risk of Lokelma? ›